Hostname: page-component-7c8c6479df-xxrs7 Total loading time: 0 Render date: 2024-03-29T09:57:04.969Z Has data issue: false hasContentIssue false

Antipsychotic polypharmacy – confusion reigns

Published online by Cambridge University Press:  02 January 2018

David Taylor*
Affiliation:
Pharmacy Department, South London and Maudsley NHS Foundation Trust, and Pharmaceutical Sciences Division, King's College London
*
Rights & Permissions [Opens in a new window]

Summary

Polypharmacy is usually employed where single drugs are considered insufficiently effective. Some polypharmacy is rational and evidence based, some neither. Antipsychotic polypharmacy remains stubbornly widespread despite condemnation of the practice by numerous bodies. The practice could not be said to be evidence based. Its persistence probably stems from a well-meaning desire to improve response and from confusion about the mechanism of action of antipsychotics. In particular, the concept that more antipsychotic(s) must always be, or might be, ‘better’ is virtually groundless. Nonetheless, some specific antipsychotic polypharmacy regimens have shown particular benefits on adverse effect profiles. Targeted, evidence-based polypharmacy may be the way forward.

Type
Editorial
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © The Royal College of Psychiatrists, 2010

Antipsychotic polypharmacy, it seems, will not just go away. Two papers in this issue re-emphasise that antipsychotic polypharmacy is widespread, poorly supported and very probably dangerous. Reference Langan and Shajahan1,Reference Tungaraza, Gupta, Jones, Poole and Slegg2 Yet the practice continues and is resistant to all kinds of quality improvement interventions. Reference Paton, Barnes, Cavanagh, Taylor and Lelliott3

Polypharmacy – is it ever justified?

In any area of medicine, the practice of polypharmacy arises as a result of the failure of single-drug regimens. Examples include the treatment of hypertension, Parkinson's disease, tuberculosis and HIV infection. In multi-episode schizophrenia, treatment failure is commonplace, with only a small proportion of patients showing a marked response to a single antipsychotic – a placebo-adjusted response rate of less than 20% is not unusual. Reference Beasley, Sanger, Satterlee, Tollefson, Tran and Hamilton4,Reference Borison, Arvanitis and Miller5 Adding another antipsychotic is one way of ‘doing something’ (or appearing to do something) to improve on this mediocre response. However, whereas the use of polypharmacy in, for example, tuberculosis has a rational pharmacological basis and a solid clinical evidence base, antipsychotic polypharmacy might be said to have neither.

Some facts about antipsychotics…

What do we know for certain about antipsychotics? They work acutely for some people and prevent relapse for others; they cause adverse effects for most people; they share an ability to modify central dopaminergic transmission; clozapine is more effective than other antipsychotics. This is the sum of what is certain. Everything else (e.g. other neurotransmitter involvement, negative symptom response, cognitive changes) is a subject of disagreement, conjecture and, one might say, some confusion.

… and popular beliefs

A good example of the type of thinking that arises from this confusion is the idea, often heard expressed on ward rounds, that increasing dopamine D2 blockade in people taking clozapine will in some way improve response. This well-meaning practice survives alongside a body of evidence which suggests that this is not the case. People on clozapine will already have been subjected to multiple antipsychotics and polypharmacy, often at high dose, and failed to respond. Reference Taylor, Young and Paton6 Also, individuals switched from a long-acting injectable antipsychotic to clozapine show no difference in response characteristics to those switched from oral antipsychotics. Reference Carpenter, Zito, Vitrai and Volavka7 Clozapine saturates D2 receptors in extra-striatal areas at normal clinical doses Reference Pilowsky, Mulligan, Acton, Ell, Costa and Kerwin8 and clinical trial evidence either suggests no advantage for clozapine–antipsychotic co-therapy, Reference Barbui, Signoretti, Mule, Boso and Cipriani9 or a minute effect not in any way clearly linked to D2-related activity. Reference Taylor and Smith10 A Cochrane review suggests that clozapine augmentation remains of uncertain value and that more research is needed. Reference Cipriani, Boso and Barbui11 Thus adding another antipsychotic to clozapine is, at least at the moment, of dubious benefit and any benefit seen is unlikely to be a result of increased D2 blockade.

Research evidence

Antipsychotic polypharmacy in general has a similar dearth of cogent support from the literature, notwithstanding the numerous individual clinical observations of clear benefit. A large meta-analysis including a number of studies from the Chinese literature Reference Correll, Rummel-Kluge, Corves, Kane and Leucht12 found a slight therapeutic advantage for antipsychotic co-therapy, but noted clear publication bias in favour of positive studies. In practice, clinicians appear to perceive antipsychotic polypharmacy to be ineffective for persistent, treatment-resistant positive psychotic symptoms. Reference Kreyenbuhl, Marcus, West, Wilk and Olfson13 The combination of typical and atypical antipsychotics seems to produce a typical response (i.e. high rates of movement disorder). Reference Taylor, Holmes, Hilton and Paton14,Reference Taylor, Mace, Mir and Kerwin15 Also, as Langan & Shajahan Reference Langan and Shajahan1 point out, antipsychotic polypharmacy very probably increases overall mortality. Reference Waddington, Youssef and Kinsella16 Other evidence suggests antipsychotic polypharmacy increases time in hospital Reference Centorrino, Goren, Hennen, Salvatore, Kelleher and Baldessarini17 and decreases cognitive performance. Reference Elie, Poirier, Chianetta, Durand, Gregoire and Grignon18 There is more contentious evidence that polypharmacy increases the risk of metabolic disturbances. Reference Taylor, Young, Esop, Paton and Walwyn19Reference Paton, Esop, Young and Taylor22 Worryingly, this apparently dangerous and poorly supported practice may be more common in Black and minority ethnic patients than in White patients. Reference Taylor, Young, Mohamed, Paton and Walwyn23

Antipsychotic dose–response: guidelines v. practice

Prescribers seem also to be confused about the dose–response relationship of antipsychotics, as practice seems to suggest that many believe that ‘more is better’. This is true up to a point, but the ‘point’ is not where you might think it is. The most efficacious dose of risperidone is 4 mg a day, Reference Correll, Frederickson, Kane and Manu24 for aripiprazole 10 mg a day, Reference Connolly and Taylor25 for haloperidol 5 mg a day, Reference Ezewuzie and Taylor26 for quetiapine 300 mg a day Reference Mace and Taylor27 and for haloperidol decanoate 100 mg a month. Reference Van Putten, Marder, Mintz and Poland28 The largest fixed-dose study to date showed olanzapine 10 mg to be just as effective as 20 mg and 40 mg a day. Reference Sparshatt, Jones and Taylor29 These observations of a low ceiling of effect tie in nicely with receptor occupancy studies suggesting saturation of receptors at low doses. Reference Taylor30 Thus, more is not better once a certain dose is reached, at least with antipsychotics used as single agents. To then assume that adding a second antipsychotic (very probably with an identical mode of action) will bring about improvement is, some might say, a leap of faith beyond reason and logic.

Nonetheless, antipsychotic polypharmacy can represent logical and advantageous prescribing practice in certain instances. For example, when switching from one antipsychotic to another, cross-tapering of antipsychotics seems entirely sensible. There is also a modicum of support for the use of as needed (p.r.n.) antipsychotics (in addition to regular antipsychotics) in rapid tranquillisation. Reference Kinon, Volavka, Stauffer, Edwards, Liu-Seifert and Chen31 Perhaps more intriguingly, although adding aripiprazole to clozapine does not improve efficacy, it does cause patients to lose weight and may also improve other metabolic parameters. Reference Agid, Mamo, Ginovart, Vitcu, Wilson and Zipursky32 Co-therapy with aripiprazole and haloperidol has been shown to normalise prolactin levels in those formerly treated with haloperidol alone. Reference Taylor, Paton and Kerwin33 Aripiprazole's very high affinity for D2 receptors Reference Fleischhacker, Heikkinen, Olie, Landsberg, Dewaele and McQuade34 provides a partial explanation for these effects and both practices represent rational prescribing likely to be of benefit to patients.

Need for more research

Clearly, confusion will continue to reign until robust clinical trials are conducted to establish the merits or otherwise of antipsychotic polypharmacy. However, there is almost no financial impetus for studies of this type to be undertaken and, in any case, proof that a particular combination has advantages over a single drug would tell us nothing about other combinations and other drugs. Moreover, the artificial clinical environment created for clinical trials might, as is always the case, tell us less than we might want to know about drug effects in the real clinical setting.

Conclusions

I was last asked to write an editorial for The Psychiatric Bulletin (the predecessor of The Psychiatrist) on antipsychotic polypharmacy in 2002. Reference Shim, Shin, Kelly, Jung, Seo and Liu35 Since then, rates of antipsychotic polypharmacy seem not to have changed. What has changed is that evidence supporting antipsychotic polypharmacy has, if anything, diminished and evidence suggesting or demonstrating harm has grown. This mounting awareness of the probable futility of antipsychotic polypharmacy is reflected in the latest guidance issued by the National Institute for Health and Clinical Excellence (NICE). Reference Burris, Molski, Xu, Ryan, Tottori and Kikuchi36 One has to hope that the audit processes demanded by NICE guidelines will at last go some way finally to reducing the extent of antipsychotic polypharmacy in UK mental health units.

Footnotes

See original paper, pp. 44–46, and review article, pp. 58–62, this issue.

Declaration of interest

D.T. has received consultancy fees, lecturing honoraria and/or research funding from AstraZeneca, Janssen-Cilag, Servier, Sanofi-Aventis, Lundbeck, Bristol-Myers Squibb, Novartis, Eli Lilly and Wyeth.

References

1 Langan, J, Shajahan, P. Antipsychotic polypharmacy: review of mechanisms, mortality and management. Psychiatrist 2009; 34: 5862.Google Scholar
2 Tungaraza, TE, Gupta, S, Jones, J, Poole, R, Slegg, G. Polypharmacy and high-dose antipsychotic regimes in the community. Psychiatrist 2009; 34: 44–6.Google Scholar
3 Paton, C, Barnes, TRE, Cavanagh, MR, Taylor, D, Lelliott, P, the POMH-UK project team. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 2008; 192: 435–9.Google Scholar
4 Beasley, CM Jr, Sanger, T, Satterlee, W, Tollefson, G, Tran, P, Hamilton, S, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996; 124: 159–67.Google Scholar
5 Borison, RL, Arvanitis, LA, Miller, BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 1996; 16: 158–69.Google Scholar
6 Taylor, DM, Young, C, Paton, C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003; 64: 30–4.Google Scholar
7 Carpenter, WT Jr, Zito, JM, Vitrai, J, Volavka, J. Hypothesis testing: is clozapine's superior efficacy dependent on moderate D2 receptor occupancy? Biol Psychiatry 1998; 43: 7983.Google Scholar
8 Pilowsky, LS, Mulligan, RS, Acton, PD, Ell, PJ, Costa, DC, Kerwin, RW. Limbic selectivity of clozapine. Lancet 1997; 350: 490–1.CrossRefGoogle ScholarPubMed
9 Barbui, C, Signoretti, A, Mule, S, Boso, M, Cipriani, A. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2009; 35: 458–68.CrossRefGoogle ScholarPubMed
10 Taylor, DM, Smith, L. Augmentation of clozapine with a second antipsychotic – a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand 2009; 119: 419–25.Google Scholar
11 Cipriani, A, Boso, M, Barbui, C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev 2009; CD006324.Google Scholar
12 Correll, CU, Rummel-Kluge, C, Corves, C, Kane, JM, Leucht, S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009; 35: 443–57.Google Scholar
13 Kreyenbuhl, J, Marcus, SC, West, JC, Wilk, J, Olfson, M. Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatr Serv 2007; 58: 983–90.Google Scholar
14 Taylor, D, Holmes, R, Hilton, T, Paton, C. Evaluating and improving the quality of risperidone prescribing. Psychiatr Bull 1997; 21: 680–3.Google Scholar
15 Taylor, D, Mace, S, Mir, S, Kerwin, R. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatry Clin Pract 2000; 4: 41–6.Google Scholar
16 Waddington, JL, Youssef, HA, Kinsella, A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998; 173: 325–9.Google Scholar
17 Centorrino, F, Goren, JL, Hennen, J, Salvatore, P, Kelleher, JP, Baldessarini, RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004; 161: 700–6.Google Scholar
18 Elie, D, Poirier, M, Chianetta, J, Durand, M, Gregoire, C, Grignon, S. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol 2009; Epub ahead of print, doi: 10.1177/0269881108100777.Google Scholar
19 Taylor, D, Young, C, Esop, R, Paton, C, Walwyn, R. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004; 185: 152–6.Google Scholar
20 Paton, C, Esop, R, Young, C, Taylor, D. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004; 110: 299305.Google Scholar
21 Taylor, D, Young, C, Mohamed, R, Paton, C, Walwyn, R. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 2005; 19: 182–6.Google Scholar
22 Correll, CU, Frederickson, AM, Kane, JM, Manu, P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007; 89: 91100.Google Scholar
23 Connolly, A, Taylor, D. Ethnicity and quality of antipsychotic prescribing among in-patients in south London. Br J Psychiatry 2008; 193: 161–2.Google Scholar
24 Ezewuzie, N, Taylor, D. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. J Psychopharmacol 2006; 20: 8690.CrossRefGoogle ScholarPubMed
25 Mace, S, Taylor, D. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS Drugs 2008; 23: 773–80.Google Scholar
26 Van Putten, T, Marder, SR, Mintz, J, Poland, RE. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 1992; 149: 500–5.Google Scholar
27 Sparshatt, A, Jones, S, Taylor, D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs 2008; 22: 4968.Google Scholar
28 Taylor, D. Establishing a dose-response relationship for haloperidol decanoate. Psychiatr Bull 2005; 29: 104–7.Google Scholar
29 Kinon, BJ, Volavka, J, Stauffer, V, Edwards, SE, Liu-Seifert, H, Chen, L, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol 2008; 28: 392400.Google Scholar
30 Agid, O, Mamo, D, Ginovart, N, Vitcu, I, Wilson, AA, Zipursky, RB, et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response. A double-blind PET study in schizophrenia. Neuropsychopharmacology 2006; 32: 1209–15.Google Scholar
31 Taylor, D, Paton, C, Kerwin, R. The Maudsley Prescribing Guidelines (9th edn). Informa Healthcare, 2007.Google Scholar
32 Fleischhacker, WW, Heikkinen, T, Olie, JP, Landsberg, W, Dewaele, P, McQuade, RD, et al. Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study. Eur Psychiatry 2008; 2 (suppl 23): s1145.Google Scholar
33 Shim, JC, Shin, JG, Kelly, DL, Jung, DU, Seo, YS, Liu, KH, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007; 164: 1404–10.Google Scholar
34 Burris, KD, Molski, TF, Xu, C, Ryan, E, Tottori, K, Kikuchi, T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381–9.Google Scholar
35 Taylor, D. Antipsychotic prescribing – time to review practice. Psychiatr Bull 2002; 26: 401–2.Google Scholar
36 National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update). NICE, 2009.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.